Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?
The primary nivo/ipi arm was q3 wks x4c, whereas the post-chemo crossover arm used q6 wks until progression. Is one schedule clearly more effective or safer than the other, or is it dealer's choice?
Community PollStarted
Do you have a preferred ipilimumab dosing schedule for MSI-H/dMMR CRC in your own practice?
86 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Medical Oncology · The University of Texas MD Anderson Cancer Center
Answered on
As ipilimumab often drives the increased toxicity of dual checkpoint inhibitors in comparison to monotherapy, multiple dosing regimens have been used across tumor types. Patients tend to do better with either short courses of ipilimumab (such as the Q3 week dosing for 4 cycles) or longer periods bet...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on
Before the CheckMate 8HW reported data compared nivolumab/ipilimumab vs nivolumab, the strongest evidence we have is from the indirect comparison from the two later-line arms, including the phase II CheckMate142 study (Lenz et al, PMID: 34637336) which showed response rates for nivolumab and nivolum...
Join for free or sign in to see the full answer